X

Trial Profile

A real-world study of apalutamide or enzalutamide in patients with non-metastatic castrate-resistant prostate cancer (nmCRPC)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary) ; Enzalutamide (Primary)
Indications Prostate cancer
Focus Adverse reactions

Most Recent Events

22 Mar 2022 Results assessing real-world burden of adverse events for apalutamide- or enzalutamide-treated patients published in the BMC Cancer
19 Mar 2021 New trial record
13 Feb 2021 Results assessing safety of apalutamide or enzalutamide in patients with non-metastatic castrate-resistant prostate cancer (nmCRPC) in real-world settings, presented at the 2021 Genitourinary Cancers Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com